GlassScriptPhysician profile
Tulika Jain
NPI 1336128909
$2,973.98
in general payments reported to CMS, 2019-2025
25 companies · $250 in 2025
The $250 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $949 · 2020: $500 · 2021: $562 · 2022: $338 · 2023: $109 · 2024: $265 · 2025: $250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $625.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $624.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $621.48 | 2019-2024 | Watchman Flx, Bodyguardian |
| Janssen Pharmaceuticals, INC | $443.41 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $409.22 | 2019-2024 | Lifevest |
| Pfizer INC. | $268.51 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $162.35 | 2019-2024 | |
| Heartflow, INC. | $156.57 | 2025 | |
| Amarin Pharma, INC. | $153.97 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $151.07 | 2019-2025 | Eliquis, Camzyos |
| Kiniksa Pharmaceuticals, LTD. | $89.91 | 2022-2023 | Arcalyst |
| Amgen INC. | $71.69 | 2019-2023 | Repatha |
| Merck Sharp & Dohme LLC | $71.19 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $52.23 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.13 | 2022-2025 | Jardiance |
| Atricure, INC. | $37.17 | 2025 | Atriclip Laa Exclusion System, Epi-Sense Guided Coagulation System With Visitrax |
| Novo Nordisk INC | $36.76 | 2024-2025 | Ozempic, Rybelsus |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $34.87 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $33.55 | 2024 | Arcalyst |
| Inspire Medical Systems, INC. | $25.14 | 2024 | Inspire |
| Regeneron Healthcare Solutions, INC. | $23.46 | 2019 | |
| Siemens Medical Solutions USA, INC. | $20.41 | 2019 | |
| Esperion Therapeutics, INC. | $20.02 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.47 | 2021 | |
| Itamar Medical INC | $13.23 | 2022 | |
| Tactile Systems Technology INC | $12.14 | 2019 | |
| Bardy Diagnostics, INC. | $7.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tulika Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.